ClinicalTrials.gg
RecruitingNCT07611721DREAM-ICUUpdated May 28, 2026

Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.

An interventional study of Continuous glucose monitor in CGM, Intensive Care (ICU) and Liver Transplant Surgery, sponsored by Institute for Clinical and Experimental Medicine. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Institute for Clinical and Experimental Medicine · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2026, registered May 2026).
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Diabetes Mellitus with a site in Czechia — 8 open to participants now, 12 under way, 3 of them phase 3. Diabetes Mellitus · Czechia.

Planned enrollment
96th of 108
62 · median 464
Started
2026
with 3 others
No phase
14 of 120
3 open now
Primary completion
2026-09
later than 4 of 11 live
Registered
120th of 120
by date
Lead sponsor
3 of 120
Institute for Clinical and Experimental Medicine

Among the 120 studies in Diabetes Mellitus with a site in Czechia, this one is the 96th largest by planned enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 120th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

8 of the 120 studies in Diabetes Mellitus with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Diabetes Mellitus with a site in Czechia, or all of them as a file.
02

Study summary

Main objective:

The goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.

On admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.

Sensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.

Sensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.

Patients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.

Calibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.

Calibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol/L).

Calibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol/L) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol/L).

Hypothesis:

  • Ho: No difference in mean absolute relative difference (MARD) between calibrated and non-calibrated sensors.
  • Ha: Calibrated sensors have lower mean absolute relative difference (δ = 4%, SD = 5%).

Further objectives:

To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.

To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.

Read the detailed description

Design:

  • Each intensive care unit patient wears two sensors (calibrated + non-calibrated).
  • 4 glucose measurements/day × 6 days = 24 measurements/subject.
  • Sequential Organ Failure Assessment (SOFA) score recorded daily.
03

Conditions studied

  • CGM
  • Intensive Care (ICU)
  • Liver Transplant Surgery
  • Solid Organ Transplantation
  • Major Abdominal Surgeries
  • Diabetes (Insulin-requiring, Type 1 or Type 2)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or over
  • Intensive care unit admission
  • Requiring blood glucose monitoring for insulin therapy

Exclusion criteria

Exclusion Criteria:

  • High-dose ascorbic acid or acetaminophen > 4g/day
  • Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Open labeled CGM

    Additional calibrations performed on CGM device during monitoring period

    Device: Continuous glucose monitor

  • Sham comparator
    Control labeled CGM

    No additional calibrations performed on CGM device during monitoring period

    Device: Continuous glucose monitor

Interventions

  • DeviceContinuous glucose monitor

    Continuous measurement of glucose from subcutaneous tissue

06

What researchers measure

Primary outcomes

  1. Calculate overall mean absolute relative difference between arms

    Analyse the difference in mean absolute relative difference (MARD) of Dexcom G7 continuous glucose monitor between calibrated and uncalibrated sensor, in patients undergoing major abdominal surgery and solid organ transplantation.

    Time frame: From enrolment to discharge from ICU care or up-to day 10

Secondary outcomes

  1. Accuracy metrics

    To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety. To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.

    Time frame: From enrolment to discharge from ICU care or up-to day 10

07

Study locations

1 of 1 sites recruiting
  • Institute of Clinical and Experimental Medice
    Prague, Czechia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2026, 8 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 8 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 28, 2026
StartActual
Jan 14, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Apr 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07611721
Lead sponsor
Institute for Clinical and Experimental Medicine
Responsible party
Marek Protuš (Physician, Department of Anaesthesiology, resuscitation and intensive medicine, Institute for Clinical and Experimental Medicine) — Principal investigator
First posted
May 28, 2026
Start date
Jan 14, 2026
Primary completion
Sep 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 28, 2026

Study contacts

Marek Protus, MD
Contact
marek.protus@ikem.cz
+420602278062
Alexander Macek, MD
Contact
alexander.macek@ikem.cz
+421910631876

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion